The qRT-PCR analysis showed that expression of Gsc was down-regulated significantly at days 1 and 28 after blast exposure and suggests that intracochlear injections using therapies which can modulate the levels/activity of Gsc in the cochlea may be an effective therapeutic strategy against blast-induced hearing impairments. The gene discussed is GSC; the disease is Hearing impairment.